Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.42 |
| ▸ | ALPL | P05186 | 5/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6568256 | 1.00 | GPR3 (0.42) | GPR3ALPLCA12CA1CA2 | |
| SCHEMBL12422184 | 0.82 | CA12 (0.61) | GPR3CA12CA1CA2CA7 | |
| SCHEMBL2090959 | 0.80 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2090961 | 0.80 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5158453 | 0.79 | ALDH1A1 (0.46) | GPR3ALPLCA12CA1CA2 | |
| SCHEMBL8302095 | 0.79 | GPR3 (0.44) | GPR3ALPLCA12CA1CA2 | |
| SCHEMBL6417045 | 0.78 | GPR3 (0.42) | GPR3ALPLCA12CA1CA2 | |
| SCHEMBL1047194 | 0.78 | MRGPRX4 (0.45) | GPR3ALPLCA12CA1CA2 | |
| SCHEMBL4513429 | 0.78 | TUBB4A (0.53) | GPR3ALPL | |
| SCHEMBL5114311 | 0.78 | ALDH1A1 (0.63) | GPR3ALPLCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483227-A1 | THE PURIFICATION OF 2-METHOXY-5-TRIFLUOROMETHOXYBENZALDEHYDE | Pfizer Products Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-6686507-B2 | IMINATION BY REACTING WITH A NITROANILINE; ISOLATING SOLID; LIQUEFACTION AND CONVERTING BACK | PFIZER INC | 2004-02-03 | — | — | US | disclosed |
| US-20030176741-A1 | Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde | PFIZER INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003074462-A1 | THE PURIFICATION OF 2-METHOXY-5-TRIFLUOROMETHOXYBENZALDEHYDE | PFIZER PRODUCTS INC. (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176741-A1 | Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde | TH, PNMT, INMT | GPR3 3251/4885ALPL 3076/4885CA12 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.